Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of "Hold" from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has earned a consensus rating of "Hold" from the twelve ratings firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $61.90.

Several equities research analysts recently issued reports on HALO shares. JPMorgan Chase & Co. lifted their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Leerink Partnrs downgraded Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Morgan Stanley downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $73.00 to $62.00 in a research note on Wednesday, May 14th. Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Finally, Leerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective for the company. in a research note on Tuesday, May 13th.

Halozyme Therapeutics Stock Up 1.3%

Shares of NASDAQ:HALO traded up $0.69 during midday trading on Thursday, hitting $54.54. 1,131,852 shares of the stock were exchanged, compared to its average volume of 1,634,035. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics has a 52-week low of $42.01 and a 52-week high of $70.51. The business's fifty day simple moving average is $57.51 and its two-hundred day simple moving average is $55.99. The company has a market capitalization of $6.72 billion, a PE ratio of 15.90, a P/E/G ratio of 0.42 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. The firm had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm's revenue was up 35.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.79 earnings per share. As a group, research analysts predict that Halozyme Therapeutics will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of Halozyme Therapeutics stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the transaction, the director now directly owns 28,611 shares of the company's stock, valued at approximately $1,727,246.07. This trade represents a 13.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CBIZ Investment Advisory Services LLC bought a new position in Halozyme Therapeutics in the 4th quarter valued at $29,000. Heck Capital Advisors LLC bought a new position in Halozyme Therapeutics in the fourth quarter valued at about $29,000. Wealth Preservation Advisors LLC acquired a new stake in Halozyme Therapeutics in the first quarter worth about $32,000. SVB Wealth LLC acquired a new stake in shares of Halozyme Therapeutics during the 1st quarter worth approximately $33,000. Finally, Bessemer Group Inc. raised its stake in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 207 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.